Embecta (EMBC) Expected to Announce Earnings on Tuesday
by Jessica Moore · The Cerbat GemEmbecta (NASDAQ:EMBC – Get Free Report) is anticipated to post its Q2 2026 results before the market opens on Tuesday, May 5th. Analysts expect Embecta to post earnings of $0.42 per share and revenue of $235.67 million for the quarter. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:00 AM ET.
Embecta (NASDAQ:EMBC – Get Free Report) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.04. The firm had revenue of $261.20 million during the quarter, compared to analyst estimates of $258.07 million. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.Embecta’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.65 earnings per share. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Embecta Trading Up 1.0%
Shares of NASDAQ EMBC traded up $0.09 during trading hours on Monday, reaching $9.32. The stock had a trading volume of 41,198 shares, compared to its average volume of 788,307. The firm has a market cap of $551.99 million, a price-to-earnings ratio of 3.94 and a beta of 1.09. The business’s fifty day moving average price is $9.26 and its two-hundred day moving average price is $11.27. Embecta has a 52-week low of $8.47 and a 52-week high of $15.55.
Analyst Ratings Changes
A number of analysts recently issued reports on the company. Mizuho lowered their price target on Embecta from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Monday, April 13th. BTIG Research reiterated a “buy” rating and issued a $25.00 price target on shares of Embecta in a report on Friday, February 6th. Wall Street Zen raised shares of Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Embecta presently has an average rating of “Hold” and an average price target of $18.50.
Check Out Our Latest Analysis on Embecta
Hedge Funds Weigh In On Embecta
A number of large investors have recently bought and sold shares of the business. Brooklyn Investment Group raised its stake in Embecta by 5.9% in the fourth quarter. Brooklyn Investment Group now owns 19,736 shares of the company’s stock worth $234,000 after buying an additional 1,098 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Embecta by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company’s stock worth $209,000 after purchasing an additional 1,110 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Embecta by 2.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after purchasing an additional 1,159 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Embecta by 1.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,271 shares of the company’s stock valued at $1,785,000 after purchasing an additional 1,520 shares during the last quarter. Finally, Larson Financial Group LLC boosted its position in shares of Embecta by 368.6% in the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares in the last quarter. Institutional investors own 93.83% of the company’s stock.
Embecta Company Profile
Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.
The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.